A 70-year-old male with a history of diabetes, hyperlipidaemia and hypertension managed with atenolol presented to his family physician with lower urinary tract symptoms (LUTS). He was prescribed terazosin. Over the course of a year he noticed worsening erectile dysfunction (ED) with difficulty maintaining a hard erection until orgasm.
Elderly patients on androgen deprivation therapy (ADT) as part of prostate cancer treatment may be at an increased risk of depression, a recent study states.
Salvage radical prostatectomy (SRP) after radiation produces good long-term survival rates in men with prostate adenocarcinoma, according to a recent study.
Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.
Targeted antibiotic prophylaxis – after a rectal swab to identify specific intestinal flora – does not appear to significantly impact the risk of urinary sepsis following a transrectal ultrasound (TRUS)-guided prostate biopsy, according to a recent study.
Conservative management appears to be the favoured option in managing non-penetrating renal trauma with urinary extravasation, according to a study presented at EAU 2018.
MRI, with or without targeted biopsy, detects more clinically significant prostate cancer and less clinically insignificant prostate cancer than the standard transrectal ultrasonography (TRUS)-guided approach, enabling more than one-quarter of patients to safely avoid a biopsy altogether.
Men with nonmetastatic castration-resistant prostate cancer (CRPC) have similar health-related quality of life (HRQoL) with apalutamide given on top of androgen deprivation therapy (ADT) vs ADT alone, according to new data from the SPARTAN (Prostate Androgen Receptor Targeting with ARN-509) trial presented at the European Association of Urology (EAU) 2018 Congress.